Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004090106 | SCV003551268 | uncertain significance | not specified | 2022-03-25 | criteria provided, single submitter | clinical testing | The c.11464A>G (p.T3822A) alteration is located in exon 75 (coding exon 75) of the HMCN1 gene. This alteration results from a A to G substitution at nucleotide position 11464, causing the threonine (T) at amino acid position 3822 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003108164 | SCV003782288 | uncertain significance | not provided | 2022-04-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with HMCN1-related conditions. This variant is present in population databases (rs776373249, gnomAD 0.004%). This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 3822 of the HMCN1 protein (p.Thr3822Ala). |
Genome- |
RCV003455751 | SCV004179882 | uncertain significance | Age related macular degeneration 1 | 2023-04-11 | criteria provided, single submitter | clinical testing |